Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in clinical failure compared with endoflas chlorophenol free (Endoflas-CF); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in clinical failure compared with endoflas (CH + ZOE + iodoform); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in clinical failure compared with zinc oxide and eugenol (ZOE) (moderate certainty).
1 finding from 1 review
Metapex (calcium hydroxide/iodoform) vs RC Fill (ZOE with iodoform)
Outcome not reported · Children with extensive decay involving the dental pulp in primary teeth
1 finding from 1 review
Assessed pain, radiolucency, root resorption, filling material anomaly (Ramar 2010); no significant differences
1 study · 64 participants
GRADE not reported
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with zinc oxide and eugenol (ZOE) (moderate certainty).
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with zinc oxide and propolis (ZOP); GRADE not reported.
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional dexamethasone injections changes maximal mouth opening (interincisal distance) compared with placebo injections (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional dexamethasone injections changes burning sensation (VAS 0-100) compared with placebo injections (very low certainty).
2 findings from 1 review
MD -52.00 [-62.04, -41.96]
1 study · 25 participants
Very low
MD -46.00 [-53.44, -38.56]
1 study · 25 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review